Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT02595424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 6, 2015
Completion date
January 1, 2029
Enrollment
67 (actual)
Sites
673

Conditions

As the registry lists them; a condition with its own page is linked.

gastric neuroendocrine carcinoma, intestinal neuroendocrine carcinoma, pancreatic neuroendocrine carcinoma